Aktieanalys

Genovis Q2 2024: Intial take – softer than anticipated - Redeye

{newsItem.title}

Redeye Publicerad: 20 Aug 08:55

Redeye sees the Q2 report coming in below estimates for both sales and EBIT. Additionally, after market close yesterday, the company announced the divestment of its antibody business. In this note, we provide our initial comments.

Länk till analysen i sin helhet: https://www.redeye.se/research/1030851/genovis-q2-2024-intial-take-softer-than-anticipated?utm_source=finwire&utm_medium=RSS

Nyheter om Genovis

Läses av andra just nu

Om aktien Genovis

Senaste nytt